ACADIA Pharmaceuticals Inc.

Equities

ACAD

US0042251084

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 11:20:09 2024-03-28 am EDT 5-day change 1st Jan Change
18.29 USD +0.49% Intraday chart for ACADIA Pharmaceuticals Inc. -0.98% -41.78%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Acadia Pharmaceuticals Insider Sold Shares Worth $317,081, According to a Recent SEC Filing MT
JPMorgan Adjusts Price Target on ACADIA Pharmaceuticals to $25 From $29, Maintains Overweight Rating MT
Transcript : ACADIA Pharmaceuticals Inc. Presents at UBS Virtual CNS Day 2024, Mar-18-2024 02:00 PM
UBS Adjusts ACADIA Pharmaceuticals Price Target to $33 From $35, Maintains Buy Rating MT
Morgan Stanley Cuts Price Target on ACADIA Pharmaceuticals to $30 From $40 After Failed Study of Pimavanserin in Negative Symptoms of Schizophrenia; Overweight Kept MT
North American Morning Briefing : Stock Futures -2- DJ
Deutsche Bank Adjusts ACADIA Pharmaceuticals Price Target to $22 From $24, Maintains Hold Rating MT
Cantor Fitzgerald Adjusts Price Target on ACADIA Pharmaceuticals to $37 From $42, Maintains Overweight Rating MT
Sector Update: Health Care Stocks Gain Premarket Tuesday MT
Baird Adjusts Price Target on ACADIA Pharmaceuticals to $31 From $40, Maintains Outperform Rating MT
Consumer Prices Tick Higher in February as US Equity Futures Turn Mixed Pre-Bell MT
Needham Lowers Price Target on ACADIA Pharmaceuticals to $32 From $36, Keeps Buy Rating MT
Oppenheimer Adjusts ACADIA Pharmaceuticals Price Target to $19 From $25, Maintains Perform Rating MT
Canaccord Genuity Adjusts Price Target on ACADIA Pharmaceuticals to $33 From $40, Keeps Buy Rating MT
JMP Securities Cuts ACADIA Pharmaceuticals Price Target to $39 From $44, Maintains Market Outperform Rating MT
Top Premarket Decliners MT
RBC Cuts Price Target on ACADIA Pharmaceuticals to $30 From $35 After Phase 3 Trial of Pimavanserin Fails to Reach Primary Endpoint; Outperform Kept MT
Mizuho Securities Downgrades ACADIA Pharmaceuticals to Neutral From Buy, Adjusts Price Target to $25 From $39 MT
North American Morning Briefing : Inflation Data Back in the Spotlight DJ
Acadia Pharmaceuticals Shares Fall After Late Study of Schizophrenia Drug Fails, Development Ends MT
Acadia Pharmaceuticals' schizophrenia drug fails in late-stage study RE
Acadia Pharmaceuticals Inc. Announces Top-Line Results from Phase 3 ADVANCE-2 Trial of Pimavanserin in Negative Symptoms of Schizophrenia CI
JPMorgan Cuts Price Target on ACADIA Pharmaceuticals to $29 From $32, Maintains Overweight Rating MT
Deutsche Bank Trims ACADIA Pharmaceuticals Price Target to $24 From $25, Maintains Hold Rating MT
Needham Trims Price Target on ACADIA Pharmaceuticals to $36 From $37, Maintains Buy Rating MT
Chart ACADIA Pharmaceuticals Inc.
More charts
Acadia Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has a portfolio of commercial stage products, in-development product opportunities, and research programs that are designed to address unmet needs in CNS disorders and rare diseases. Its pipeline includes NUPLAZID (pimavanserin), DAYBUE (trofinetide), ACP-101, ACP-204, and Antisense Oligonucleotide (ASO) Programs. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. Trofinetide is a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 (IGF-1) designed to treat the core symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
21
Last Close Price
18.2 USD
Average target price
29.31 USD
Spread / Average Target
+61.04%
Consensus